This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioLineRx: Tuesday's Hot Hep C Drug Stock

Updated with current stock price.

JERUSALEM ( TheStreet) -- A tiny Israeli drug maker that few investors have ever heard of announces a licensing deal Tuesday with a French company similarly unknown, but the deal involves an oral hepatitis C pill so shares of the Israeli company doubling in value.

Just another day inside Wall Street's ever-expanding hepatitis C bubble.

BioLineRx (BLRX) shares are up $3.45, or 104%, to $6.75 after announcing the licensing deal for hepatitis C drug BL-8020, developed by the privately held French firm Genoscience. Almost 5 million BioLineRx shares have traded hands Tuesday already, blowing away the stock's average daily volume of a miniscule 3,600 shares.

Terms of the BioLineRx-Genoscience deal were not disclosed.

Little is known about BL-8020, which is still in preclinical testing, meaning the drug hasn't yet been studied in humans. But with all of Wall Street looking for the next hot hepatitis C drug stock, the mere mention of a potentially new oral therapy for the viral liver disease was enough to make BioLineRx the hot speculative biotech trade for Tuesday morning, fueled by a robust Twitter buzz.

BL-8020 may belong to the class of direct-acting antiviral agents known as protease inhibitors, according to an overview of the drug discovery research in hepatitis C noted on Genoscience's web site. Both Vertex Pharmaceuticals' (VRTX) Incivek and Merck's (MRK) Victrelis are both protease inhibitors and most of the other big Hep C players, including Johnson & Johnson (JNJ - Get Report), Gilead Sciences (GILD - Get Report), Abbott (ABT) and Bristol-Myers Squibb (BMY - Get Report), already have protease inhibitors in development.

Achillion Pharmaceuticals (ACHN - Get Report) is also developing a protease inhibitor and has been seeking a partner for the drug or a suitor to buy the entire company.

If you missed Tuesday's BioLineRx move, the next Hep C-related stock action could come early next month when Bristol-Myers Squibb is expected to close out its $2.5 billion tender offer for Inhibitex (INHX). Around the same time, Inhibitex (or Bristol) is expected to announce early data from a phase II study of INX-189, the company's lead hepatitis C drug candidate.

Investors are also waiting for Idenix Pharmaceuticals (IDIX) to announce the FDA's decision on lifting a clinical hold on IDX184, which will allow the company to push the hepatitis C drug into additional clinical studies. [Or perhaps, clear the way for Idenix to be acquired.]
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACHN $5.93 -0.50%
BLRX $0.92 -4.50%
BMY $61.00 -0.03%
GILD $87.68 0.49%
JNJ $101.58 -0.38%


Chart of I:DJI
DOW 15,910.56 -103.82 -0.65%
S&P 500 1,856.08 +3.87 0.21%
NASDAQ 4,297.86 +29.0970 0.68%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs